AVADEL PHARMACEUTICALS PLC's ticker is AVDL and the CUSIP is 05337M104. A total of 86 filers reported holding AVADEL PHARMACEUTICALS PLC in Q3 2021. The put-call ratio across all filers is 0.11 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $9,965,528 | -37.5% | 967,527 | 0.0% | 3.05% | +9.0% |
| Q2 2023 | $15,944,845 | +23.5% | 967,527 | -31.4% | 2.80% | +4.9% |
| Q1 2023 | $12,910,186 | +173.4% | 1,409,409 | +113.7% | 2.67% | +162.6% |
| Q4 2022 | $4,721,368 | +42.9% | 659,409 | 0.0% | 1.02% | +31.9% |
| Q3 2022 | $3,304,000 | +105.3% | 659,409 | 0.0% | 0.77% | +79.5% |
| Q2 2022 | $1,609,000 | -64.3% | 659,409 | 0.0% | 0.43% | -62.2% |
| Q1 2022 | $4,504,000 | -15.5% | 659,409 | 0.0% | 1.13% | +9.7% |
| Q4 2021 | $5,328,000 | -1.0% | 659,409 | +20.1% | 1.03% | +22.4% |
| Q3 2021 | $5,383,000 | +45.6% | 549,250 | 0.0% | 0.84% | +85.3% |
| Q2 2021 | $3,696,000 | -25.6% | 549,250 | 0.0% | 0.46% | -50.2% |
| Q1 2021 | $4,965,000 | +71.1% | 549,250 | +26.5% | 0.92% | +213.7% |
| Q4 2020 | $2,901,000 | – | 434,250 | – | 0.29% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| WEALTH EFFECTS LLC | 2,305,017 | $18,625,000 | 7.73% |
| COWEN AND COMPANY, LLC | 3,732,778 | $30,161,000 | 2.74% |
| GENDELL JEFFREY L | 2,446,299 | $19,766,000 | 1.60% |
| Asymmetry Capital Management, L.P. | 369,134 | $2,983,000 | 1.58% |
| Vivo Capital, LLC | 2,937,093 | $23,732,000 | 1.43% |
| Samsara BioCapital, LLC | 659,409 | $5,328,000 | 1.03% |
| Altium Capital Management LP | 440,589 | $3,560,000 | 0.98% |
| Knott David M Jr | 258,198 | $2,086,000 | 0.71% |
| RTW INVESTMENTS, LP | 5,741,939 | $46,395,000 | 0.68% |
| FRAZIER MANAGEMENT LLC | 951,814 | $7,691,000 | 0.59% |